Our Pricing

Mysimba vs Ozempic UK Comparison: Which Weight Loss Treatment Is Right for You?

Published on: June 03, 2026

Choosing between treatments requires understanding how each works. This mysimba vs ozempic uk comparison examines two fundamentally different approaches to weight management, helping you make an informed decision with guidance from our UK-registered clinical team. At Cured Pharmacy, we offer transparent pricing and expert consultations to determine which option suits your individual circumstances.

How Mysimba and Ozempic Work: Different Mechanisms Explained

Mysimba is an oral tablet combining naltrexone 8mg and bupropion 90mg, working centrally on the brain's reward and appetite pathways [1]. It modulates neurotransmitter activity in the hypothalamus and mesolimbic reward system, reducing food cravings and helping patients feel satisfied with smaller portions. Unlike injectable treatments, Mysimba requires daily oral administration with gradual dose escalation over four weeks.

Ozempic contains semaglutide, a GLP-1 receptor agonist administered via weekly subcutaneous injection. It mimics the natural hormone GLP-1, slowing gastric emptying, enhancing insulin secretion, and reducing appetite through both peripheral and central mechanisms [2]. While Ozempic is primarily licensed for type 2 diabetes management in the UK, its sister product Wegovy contains the same active ingredient and is specifically licensed for weight management.

The fundamental difference lies in their approach: Mysimba targets neurological appetite regulation through oral medication, whilst semaglutide-based treatments work through hormonal pathways via injection. This distinction affects everything from administration convenience to side effect profiles and clinical outcomes.

Clinical Efficacy: Mysimba vs Ozempic Weight Loss Results

In the COR-I trial, patients taking Mysimba achieved an average weight loss of 5-6% of their initial body weight over 56 weeks when combined with lifestyle modifications [1]. Approximately 50% of participants achieved at least 5% weight reduction, whilst 25% reached the 10% threshold. These results demonstrate consistent but moderate efficacy for oral neurological appetite modulation.

Semaglutide demonstrates significantly greater weight reduction in clinical trials. The STEP 1 trial showed participants on semaglutide 2.4mg achieved an average 14.9% body weight reduction over 68 weeks, with 86.4% of patients losing at least 5% and 69.1% achieving 10% or greater reduction [2]. These outcomes represent substantially higher efficacy compared to oral appetite modulators, though individual responses vary considerably.

It's essential to understand that clinical trial results represent averages under controlled conditions with intensive lifestyle support. Your individual response depends on multiple factors including baseline weight, adherence to dietary modifications, physical activity levels, and metabolic characteristics. Both treatments require clinical assessment and ongoing monitoring by UK prescribers.

Realistic Expectations for Weight Loss Outcomes

Neither medication guarantees specific weight loss amounts, and both work most effectively when combined with reduced-calorie nutrition and increased physical activity. Our clinical team at Cured Pharmacy emphasises that sustainable weight management requires comprehensive lifestyle changes alongside pharmacological support. Subject to prescriber approval, treatment selection considers your medical history, previous weight loss attempts, and personal preferences regarding administration method.

Side Effects and Tolerability: What UK Patients Experience

Mysimba's most common side effects relate to its neurological mechanism, including nausea (affecting approximately 30% of users initially), headache, constipation, dizziness, and insomnia [1]. These effects typically diminish after the first month as patients complete dose escalation. Mysimba carries specific contraindications including uncontrolled hypertension, seizure disorders, eating disorders, and concurrent use of opioid medications. Blood pressure monitoring is required during treatment.

Semaglutide-based treatments predominantly cause gastrointestinal side effects, with nausea being most common (affecting 20-44% of patients), alongside vomiting, diarrhoea, and constipation [2]. These effects usually improve over time, particularly with gradual dose escalation. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid effects. The injectable administration route may concern some patients, though modern pen devices make self-injection straightforward.

Tolerability profiles differ significantly between these treatments. Mysimba's neurological side effects may prove challenging for patients sensitive to stimulant-like effects, whilst semaglutide's gastrointestinal effects can be managed through dietary adjustments and slower dose titration. Your UK prescriber will assess which side effect profile aligns better with your medical history and lifestyle.

Suitability and Contraindications: Who Can Use Each Treatment

Mysimba is typically prescribed for adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities, subject to prescriber assessment [3]. Absolute contraindications include uncontrolled hypertension, seizure history, eating disorders, bipolar disorder, hepatic impairment, and current opioid use. Patients taking certain antidepressants or with cardiovascular disease require careful evaluation. The oral route suits those uncomfortable with injections or preferring tablet-based treatment.

Semaglutide-based treatments share similar BMI criteria but have different contraindication profiles. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 represent absolute contraindications [2]. Patients with diabetic retinopathy, renal impairment, or history of pancreatitis require specialist assessment. The injectable format provides consistent absorption and eliminates concerns about gastrointestinal medication absorption issues.

Pregnancy and breastfeeding contraindicate both treatments. Women of childbearing potential require reliable contraception during treatment and for specified periods after discontinuation. Your clinical assessment at Cured Pharmacy includes comprehensive review of medical history, current medications, and individual risk factors to determine appropriate treatment selection.

Special Considerations for UK Patients

Patients with type 2 diabetes may find semaglutide-based options particularly suitable given the additional glycaemic benefits, though this requires coordination with existing diabetes management. Those with hypertension concerns might prefer semaglutide over Mysimba, which requires blood pressure monitoring. Our superintendent pharmacist Tarun Kumar ensures all clinical decisions align with current MHRA guidance and NICE recommendations for weight management interventions.

Administration and Treatment Schedules: Practical Considerations

Mysimba requires daily oral administration following a specific escalation schedule. Patients begin with one tablet daily in week one, increasing to one tablet twice daily in week two, then two tablets in the morning and one in the evening during week three, reaching the maintenance dose of two tablets twice daily by week four [1]. This gradual increase helps minimise side effects. Treatment continues long-term, with response assessment at 16 weeks.

Semaglutide-based injections follow a weekly schedule using pre-filled pen devices. Treatment begins at lower doses with monthly increases over 16-20 weeks until reaching the maintenance dose, allowing gradual tolerance development [2]. The once-weekly administration offers convenience compared to daily tablets, though it requires proper injection technique and refrigerated storage before first use.

Adherence patterns differ between daily oral and weekly injectable formats. Some patients prefer the routine of daily tablets, whilst others value the convenience of weekly injections. Missing doses affects efficacy differently: missed Mysimba tablets should be skipped if near the next scheduled dose, whilst delayed semaglutide injections can be administered within five days of the scheduled day. Your prescriber will provide detailed administration guidance specific to your chosen treatment.

Making Your Decision: Mysimba vs Ozempic UK Treatment Selection

Treatment selection depends on multiple individual factors rather than a universal 'best' option. Consider Mysimba if you prefer oral medication, cannot use injectable treatments due to needle phobia or practical constraints, or have contraindications to GLP-1 therapies. The neurological mechanism may suit patients who identify strong psychological components to their eating patterns, subject to appropriate psychiatric screening.

Semaglutide-based options may be preferable if you seek higher average weight loss outcomes demonstrated in clinical trials, have type 2 diabetes requiring glycaemic management, or prefer weekly administration over daily tablets. The injectable format suits patients comfortable with self-administration and requiring medication that bypasses gastrointestinal absorption variability.

At Cured Pharmacy, our free online consultation takes under three minutes and allows UK prescribers to assess your complete medical picture. We offer transparent upfront pricing and stock genuine UK-licensed medications only. Whether you proceed with Mysimba from £135.00 or explore alternative options like Wegovy or Mounjaro, our clinical team ensures you receive appropriate treatment matching your individual circumstances, medical history, and weight management goals.

Next Steps: Starting Your Weight Loss Journey

Begin with our confidential online assessment, completed entirely through our secure platform. Our UK-registered prescribers review your submission, considering your BMI, medical history, current medications, and previous weight loss attempts. If treatment is deemed suitable and safe, we dispense your medication in discreet packaging with comprehensive instructions. Ongoing support ensures you understand administration, recognise side effects requiring medical attention, and optimise your treatment outcomes through evidence-based lifestyle modifications.

Scientific References

1. Greenway, F. L., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2014). Weight management: lifestyle services for overweight or obese adults (PH53). NICE guideline. https://www.nice.org.uk/guidance/ph53 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modifications alongside pharmacological treatment.